title: Ryanodine contracture threshold times for diagnosis of malignant hyperthermia susceptibility: an experimental approach from a single laboratory.
abstract: OBJECTIVE
  To define threshold times for ryanodine contracture testing (RCT) using skeletal muscle specimens from malignant hyperthermia-susceptible (MHS) and control individuals.
  
  
  METHODS
  Prospective study.
  
  
  METHODS
  Malignant hyperthermia (MH) laboratory at a university hospital.
  
  
  METHODS
  8 patients with previous fulminant MH and 53 control patients undergoing in vitro contracture test (IVCT) for diagnosis of MH susceptibility.
  
  
  METHODS
  Biopsies of the quadriceps femoris muscle were performed with a 3-in-1 nerve block, with spinal anesthesia, or with trigger-free general anesthesia.
  
  
  RESULTS
  Patients were classified as MHS, MH normal (MHN), or MH equivocal (MHE) by the IVCT according to the protocol of the European MH Group (EMHG). Ryanodine 1 microM was added as a bolus to the organ bath to extra vital muscle specimens. Contracture levels were defined as: 1 = start of contracture (OT; min); 2 = time (min) to reach a contracture of 2 mN, and 3 = time (min) to reach a contracture of 10 mN. The effects of ryanodine on contracture responses were measured. Ryanodine induced contractures in all specimens. MHS specimens reached all defined contracture levels significantly sooner than did the controls. Ryanodine contracture test enables a clear discrimination of MHS specimens from controls at contracture levels of OT and 2 mN, whereas at 10 mN a small overlap was observed.
  
  
  CONCLUSIONS
  Using this test, which is an experimental approach from a single laboratory, an assignment to MHS or MHN is possible. To define contracture levels for RCT more precisely and to agree on commonly used thresholds, multicenter studies with larger numbers of patients are required.
authors.affiliation: Department of Anesthesiology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. weisshorn@uke.uni-hamburg.de
authors.forename: Ralf
authors.initials: R
authors.lastname: Weisshorn
authors.forename: Frank
authors.initials: F
authors.lastname: Wappler
authors.forename: Marko
authors.initials: M
authors.lastname: Fiege
authors.forename: Mark U
authors.initials: MU
authors.lastname: Gerbershagen
authors.forename: Kerstin
authors.initials: K
authors.lastname: Kolodzie
authors.forename: Patrick
authors.initials: P
authors.lastname: Alberts
authors.forename: Ernst-Peter
authors.initials: EP
authors.lastname: Horn
authors.forename: Jochen
authors.initials: J
authors.lastname: Schulte Am Esch
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D004198:Disease Susceptibility / Q000175:diagnosis*; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008305:Malignant Hyperthermia / Q000209:etiology* / Q000503:physiopathology; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects*; D011446:Prospective Studies; D012433:Ryanodine / Q000494:pharmacology*
chemical_list: D012433:Ryanodine